CDA | Evidence Driven
CDA | Evidence Driven

Octreotide Long Acting Release and Everolimus for Recurrent Meningiomas

Details

Files
Project Status:
Completed
Project Line:
Reference List
Project Sub Line:
Summary of Abstracts
Project Number:
RB1631-000
Effective finish date:

Question

  1. What literature describes the potential clinical benefits and harms of octreotide long-acting release and everolimus in patients with recurrent meningiomas?

Key Message

We found 2 non-randomized studies describing the benefits and harms of octreotide long-acting release and everolimus in patients with recurrent meningiomas.

Files

Octreotide Long Acting Release and Everolimus for Recurrent Meningiomas View PDF
Last Updated : September 2, 2022